Compare Stocks

Date Range: 

 Antares PharmaIntersect ENTOraSure TechnologiesInvo BioscienceAnika Therapeutics
SymbolNASDAQ:ATRSNASDAQ:XENTNASDAQ:OSUROTCMKTS:IVOBNASDAQ:ANIK
Price Information
Current Price$3.83$21.04$9.86$3.80$41.98
52 Week RangeBuyHoldBuyN/ABuy
MarketRank™
Overall Score1.81.51.70.51.5
Analysis Score3.52.23.40.01.5
Community Score2.82.82.82.62.5
Dividend Score0.00.00.00.00.0
Ownership Score0.81.71.70.01.7
Earnings & Valuation Score1.90.60.60.01.9
Analyst Ratings
Consensus RecommendationBuyHoldBuyN/ABuy
Consensus Price Target$6.00$25.67$17.60N/A$43.00
% Upside from Price Target56.66% upside21.99% upside78.50% upsideN/A2.43% upside
Trade Information
Market Cap$646.50 million$697.18 million$709.39 million$599.16 million$603.13 million
Beta1.441.340.04-0.811.1
Average Volume1,166,061204,1861,091,58543,036137,899
Sales & Book Value
Annual Revenue$123.86 million$109.14 million$154.60 million$490,000.00$114.51 million
Price / Sales5.226.394.591,222.785.27
CashflowN/AN/A$0.19 per shareN/A$2.68 per share
Price / CashN/AN/A50.78N/A15.64
Book Value$0.33 per share$3.75 per share$4.98 per share($0.02) per share$20.21 per share
Price / Book11.615.611.98-190.002.08
Profitability
Net Income$-2,030,000.00$-42,990,000.00$16.66 million$-3,080,000.00$27.19 million
EPS($0.01)($1.37)$0.13N/A$2.05
Trailing P/E Ratio63.84N/AN/AN/AN/A
Forward P/E Ratio15.96N/A10.9646.64
P/E GrowthN/AN/AN/AN/AN/A
Net Margins6.64%-71.96%-9.05%-166.95%-5.18%
Return on Equity (ROE)16.48%-55.81%-3.51%N/A2.63%
Return on Assets (ROA)6.69%-40.23%-3.13%-85.23%1.91%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.53%0.72%N/AN/A0.09%
Current Ratio2.47%11.28%8.14%1.05%6.48%
Quick Ratio2.08%10.29%7.32%1.02%4.95%
Ownership Information
Institutional Ownership Percentage39.92%84.32%98.13%N/A95.01%
Insider Ownership Percentage5.90%3.50%1.70%20.64%2.53%
Miscellaneous
Employees1854065702277
Shares Outstanding168.80 million33.14 million71.95 million157.67 million14.37 million
Next Earnings Date8/5/2021 (Estimated)5/10/2021 (Confirmed)8/4/2021 (Estimated)N/A7/29/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Anika Therapeutics (NASDAQ:ANIK) Issues  Earnings ResultsAnika Therapeutics (NASDAQ:ANIK) Issues Earnings Results
americanbankingnews.com - May 7 at 5:04 PM
Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call PresentationAnika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 7 at 11:27 AM
Anika Therapeutics Inc (ANIK) Q1 2021 Earnings Call TranscriptAnika Therapeutics Inc (ANIK) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 7 at 9:37 AM
BRIEF-Anika Therapeutics Q1 Adjusted Earnings Per Share $0.06BRIEF-Anika Therapeutics Q1 Adjusted Earnings Per Share $0.06
msn.com - May 6 at 6:36 PM
Anika Therapeutics (NASDAQ:ANIK) Shareholders Have Enjoyed A 19% Share Price GainAnika Therapeutics (NASDAQ:ANIK) Shareholders Have Enjoyed A 19% Share Price Gain
nasdaq.com - May 5 at 7:32 AM
Dermal Filler Market Projections 2026 by Top Players Allergan, Merz Pharma, Galderma, Anika Therapeutics, Cytophil, Sinclair Pharma, Suneva MedicalDermal Filler Market Projections 2026 by Top Players Allergan, Merz Pharma, Galderma, Anika Therapeutics, Cytophil, Sinclair Pharma, Suneva Medical
openpr.com - May 4 at 10:38 AM
Reviewing Anika Therapeutics (NASDAQ:ANIK) and CVR Medical (OTCMKTS:CRRVF)Reviewing Anika Therapeutics (NASDAQ:ANIK) and CVR Medical (OTCMKTS:CRRVF)
americanbankingnews.com - May 4 at 8:30 AM
ANIK: Lowering target price to $37.00ANIK: Lowering target price to $37.00
finance.yahoo.com - April 30 at 12:38 AM
Anika Therapeutics (ANIK) Scheduled to Post Earnings on ThursdayAnika Therapeutics (ANIK) Scheduled to Post Earnings on Thursday
americanbankingnews.com - April 29 at 3:18 AM
Outlook on the Hyaluronic Acid Global Market to 2025 - Featuring Anika Therapeutics, Allergan and Genzyme Among Others - ResearchAndMarkets.comOutlook on the Hyaluronic Acid Global Market to 2025 - Featuring Anika Therapeutics, Allergan and Genzyme Among Others - ResearchAndMarkets.com
apnews.com - April 28 at 9:59 AM
Osteoarthritis Therapeutic Market to Witness Huge Growth by 2025 | Sanofi, Horizon Therapeutics, Johnson & JohnsonOsteoarthritis Therapeutic Market to Witness Huge Growth by 2025 | Sanofi, Horizon Therapeutics, Johnson & Johnson
marketwatch.com - April 27 at 8:48 AM
Lip Augmentation Market 2021 Production, Revenue, Growth Rate, Price and Gross Margin, Opportunities and Forecast 2027 with Top Growth CompaniesLip Augmentation Market 2021 Production, Revenue, Growth Rate, Price and Gross Margin, Opportunities and Forecast 2027 with Top Growth Companies
marketwatch.com - April 23 at 6:50 PM
ANIK: Rating decreased to a SELLANIK: Rating decreased to a SELL
finance.yahoo.com - April 22 at 10:22 PM
Anika to Issue First Quarter 2021 Financial...Anika to Issue First Quarter 2021 Financial...
benzinga.com - April 17 at 7:43 AM
Financial Contrast: CVR Medical (OTCMKTS:CRRVF) and Anika Therapeutics (NASDAQ:ANIK)Financial Contrast: CVR Medical (OTCMKTS:CRRVF) and Anika Therapeutics (NASDAQ:ANIK)
americanbankingnews.com - April 17 at 6:14 AM
Anika to Issue First Quarter 2021 Financial Results on Thursday, May 6, 2021Anika to Issue First Quarter 2021 Financial Results on Thursday, May 6, 2021
finance.yahoo.com - April 15 at 6:00 PM
Artificial Cartilage Implant Market 2021 Booming Strategies of Top Companies, Progression Status and Business Trends to 2031Artificial Cartilage Implant Market 2021 Booming Strategies of Top Companies, Progression Status and Business Trends to 2031
marketwatch.com - April 9 at 7:11 AM
Hemostats Market Sparkling Key Players Revenue, Shares, Analysis and Forecasts to 2027Hemostats Market Sparkling Key Players Revenue, Shares, Analysis and Forecasts to 2027
marketwatch.com - April 9 at 7:11 AM
Anika Therapeutics: Primed To Outperform The Market, Says Top BloggerAnika Therapeutics: Primed To Outperform The Market, Says Top Blogger
finance.yahoo.com - March 30 at 5:29 PM
Anika Therapeutics (ANIK) Presents At Sidoti Virtual Spring Investor Conference - SlideshowAnika Therapeutics (ANIK) Presents At Sidoti Virtual Spring Investor Conference - Slideshow
seekingalpha.com - March 26 at 7:27 PM
Osteoarthritis therapeutics is expected to grow at a CAGR of around 7.7% from 2020 to 2027 | ARCOsteoarthritis therapeutics is expected to grow at a CAGR of around 7.7% from 2020 to 2027 | ARC
marketwatch.com - March 9 at 8:24 AM
Analysts Have Been Trimming Their Anika Therapeutics, Inc. (NASDAQ:ANIK) Price Target After Its Latest ReportAnalysts Have Been Trimming Their Anika Therapeutics, Inc. (NASDAQ:ANIK) Price Target After Its Latest Report
nasdaq.com - March 6 at 8:10 AM
Anika Therapeutics, Inc. (NASDAQ:ANIK) Just Reported, And Analysts Assigned A US$47.50 Price TargetAnika Therapeutics, Inc. (NASDAQ:ANIK) Just Reported, And Analysts Assigned A US$47.50 Price Target
finance.yahoo.com - March 6 at 8:10 AM
Osteoarthritis Therapeutics Market Size Surpass Around USD 11.5 Billion by 2027Osteoarthritis Therapeutics Market Size Surpass Around USD 11.5 Billion by 2027
marketwatch.com - March 5 at 6:18 PM
Anika Therapeutics, Inc. 2020 Q4 - Results - Earnings Call PresentationAnika Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 5 at 2:16 PM
DateCompanyBrokerageAction
10/1/2020Antares PharmaRaymond JamesReiterated Rating
8/10/2020Antares PharmaHC WainwrightReiterated Rating
6/21/2020Antares PharmaPiper SandlerReiterated Rating
6/21/2020Antares PharmaLADENBURG THALM/SH SHReiterated Rating
2/25/2019Antares PharmaCowenInitiated Coverage
11/6/2018Antares PharmaJefferies Financial GroupBoost Price Target
8/17/2018Antares PharmaPiper Jaffray CompaniesReiterated Rating
3/16/2021Intersect ENTSVB LeerinkBoost Price Target
1/11/2021Intersect ENTCanaccord GenuityUpgrade
11/19/2020Intersect ENTBTIG ResearchUpgrade
10/8/2020Intersect ENTJPMorgan Chase & Co.Downgrade
8/7/2020Intersect ENTGuggenheimUpgrade
8/4/2020Intersect ENTOppenheimerReiterated Rating
4/15/2020Intersect ENTBank of AmericaDowngrade
5/6/2021OraSure TechnologiesLake Street CapitalLower Price Target
3/2/2021OraSure TechnologiesCitigroupLower Price Target
8/21/2020OraSure TechnologiesEvercore ISIInitiated Coverage
4/21/2020OraSure TechnologiesStephensInitiated Coverage
12/16/2020Anika TherapeuticsBarrington ResearchUpgrade
1/21/2020Anika TherapeuticsSidotiUpgrade
1/10/2020Anika TherapeuticsFirst AnalysisUpgrade
11/5/2019Anika TherapeuticsBWS FinancialInitiated Coverage
2/28/2019Anika TherapeuticsSingular ResearchReiterated Rating
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.